Radiotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Radiotherapy, including details on cancer treatment, side effects.

Radiographic response and clinical toxicity following SBRT for stage I lung cancer.

Bradley J

Department of Radiation Oncology, Washington University School of Medicine, Alvin J. Siteman Cancer Center, St. Louis, Missouri, USA. jbradley@wustl.edu

Clinical outcomes following stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) are excellent, with local control rates ranging from 80% to 95% in medically inoperable patients. Toxicity following SBRT has been lower than expected, with exception for grade 3 to 5 events occurring in patients treated with high doses to mediastinal structures. In considering a randomized head-to-head comparison of SBRT versus surgery for stage I lung cancer, the interpretation of clinical response based on imaging is of great importance. This is because of the opportunity to salvage SBRT local failure with surgery in operable patients. The current literature is reviewed with respect to computed tomography (CT) and positron emission tomography (PET) with respect to response following SBRT. The reported toxicities following SBRT for both peripheral and central lung cancers are also reviewed.

Published 2 July 2007 in J Thorac Oncol, 2(7): S118-24.
Full-text of this article is available online (may require subscription).

© 2004-2008 Radiotherapy Research Today. All Rights Reserved.